We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Microbial Etiology of Ventilator-associated Pneumonia in COVID-19 Infected Patients

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04344509
Recruitment Status : Unknown
Verified April 2020 by Poitiers University Hospital.
Recruitment status was:  Not yet recruiting
First Posted : April 14, 2020
Last Update Posted : June 2, 2020
Sponsor:
Information provided by (Responsible Party):
Poitiers University Hospital

Study Description
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Brief Summary:
National multicentric observational retrospective case-control study comparing the relative frequency of the various microorganisms responsible for VAP in patients infected or not by SARS-CoV-2 and their resistance to antibiotics.

Condition or disease Intervention/treatment
Ventilator Associated Pneumonia Other: Bacterial species isolated

Study Design
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Layout table for study information
Study Type : Observational
Estimated Enrollment : 10000 participants
Observational Model: Case-Control
Time Perspective: Retrospective
Official Title: Microbial Etiology of Ventilator-associated Pneumonia (VAP) in COVID-19 Infected Patients
Estimated Study Start Date : June 2020
Estimated Primary Completion Date : September 2020
Estimated Study Completion Date : December 2020

Resource links provided by the National Library of Medicine


Groups and Cohorts
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Group/Cohort Intervention/treatment
COVID19-positive patients Other: Bacterial species isolated
in the respiratory specimen
COVID19-negative patients Other: Bacterial species isolated
in the respiratory specimen


Outcome Measures
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Primary Outcome Measures :
  1. Prevalence of the microorganisms responsible for VAP among patients infected or not by the SARS-CoV-2 [ Time Frame: 1 month ]

Secondary Outcome Measures :
  1. Prevalence of multi-drug resistant bacteria responsible for VAP among patients infected or not by the SARS-CoV-2 [ Time Frame: 1 month ]

Eligibility Criteria
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 100 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All patients with microbiologically confirmed VAP with pulmonary samples collected from March 15 to April 15 in France.
Criteria

Inclusion Criteria:

  • All patients with microbiologically confirmed VAP with pulmonary samples collected from March 15 to April 15 in France.

Exclusion Criteria:

  • All patients with microbiologically confirmed VAP with pulmonary samples collected from March 15 to April 15 in France.
Contacts and Locations
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04344509


Contacts
Layout table for location contacts
Contact: Christophe BURUCOA 549443889 ext +33 christophe.burucoa@chu-poitiers.fr

Sponsors and Collaborators
Poitiers University Hospital
More Information
Go to 
Top of Page Study Description Study Design Groups and Cohorts Outcome Measures Eligibility Criteria Contacts and Locations More Information
Layout table for additonal information
Responsible Party: Poitiers University Hospital
ClinicalTrials.gov Identifier: NCT04344509    
Other Study ID Numbers: PAVM COVID
First Posted: April 14, 2020    Key Record Dates
Last Update Posted: June 2, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Pneumonia
Pneumonia, Ventilator-Associated
Respiratory Tract Infections
Infections
Lung Diseases
Respiratory Tract Diseases
 Healthcare-Associated Pneumonia
Cross Infection
Iatrogenic Disease
Disease Attributes
Pathologic Processes